We found that serum IL-5, IL-8, CXCL9, PDGF-BB, TGF-α, and VEGF-A were elevated in the long survivors group among HCC patients who received sorafenib compared to those who received HAIC. Here, TGFA is linked to hepatocellular carcinoma.